<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: Patients with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> and intermedia show a marked variability of serum indirect <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>In this paper we tested the hypothesis related to the variability of the glucuronidation <z:chebi fb="0" ids="16990">bilirubin</z:chebi> rate which depends on the configuration of the A(TA)nTAA motif of the UGT1*1 glucuronosyltransferase gene promoter </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: We studied the configuration of the A(TA)nTAA motif in 26 patients with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> and 34 with <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In patients with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> and in those with <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> significantly higher <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels were found in patients with the (TA)7/(TA)7 genotype, than in those with the (TA)7/(TA)6 or (TA)6/(TA)6 genotype </plain></SENT>
<SENT sid="4" pm="."><plain>INTERPRETATION AND CONCLUSIONS: These results indicate that the (TA)7/(TA)7 genotype, the configuration found in patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, is capable of modifying the clinical phenotype of <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">homozygous beta-thalassemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This is an example of the role played by co-inherited modifying gene(s) on the extent of clinical <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of monogenic disorders </plain></SENT>
</text></document>